Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 7/20 | 0.33 |
| ▸ | CA2 | P00918 | 7/20 | 0.33 |
| ▸ | CA9 | Q16790 | 7/20 | 0.33 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.30 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.30 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.30 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.30 |
| ▸ | GRM6 | O15303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796470 | 0.78 | CA1 (0.33) | CA12CA2CA9CA1CA14 | |
| SCHEMBL1797123 | 0.73 | VCAM1 (0.37) | VCAM1XDHGRIA1GRIA2GRIA3 | |
| SCHEMBL18430522 | 0.73 | VCAM1 (0.42) | VCAM1XDHGRIA1GRIA2GRIA3 | |
| SCHEMBL14305192 | 0.73 | VCAM1 (0.37) | VCAM1XDHGRIA1GRIA2GRIA3 | |
| SCHEMBL18430405 | 0.73 | GRIN2D (0.38) | VCAM1XDHGRIA1GRIA2GRIA3 | |
| SCHEMBL332660 | 0.68 | CA12 (0.31) | CA12CA2CA9CA1CA14 | |
| SCHEMBL1523769 | 0.67 | CA2 (0.41) | CA12CA2CA9CA1VCAM1 | |
| SCHEMBL27629298 | 0.67 | RECQL (0.34) | CA12CA2CA9CA1CA14 | |
| SCHEMBL18430519 | 0.67 | ALDH1A1 (0.35) | VCAM1GRM6MAPT | |
| SCHEMBL332661 | 0.66 | CA2 (0.34) | CA2CA1XDHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951800-B2 | Anti-infective agents | ABBOTT LABORATORIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120753-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008011337-A1 | HCV INHIBITORS | ABBOTT LABORATORIES (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | NQO2, RSU1, RRS1 | IDO1 848/4885CA12 4833/4885CA2 3689/4885 |
| US-20100120753-A1 | Anti-Infective Agents | RSU1, NQO2, RRS1 | IDO1 1058/4885CA12 4846/4885CA2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.